Filip Babić, P. Čačić, Dominik Kralj, A. Bišćanin, V. Tomašić, I. Burčul, Doris Ogresta Kordej, Z. Dorosulić, D. Hrabar
{"title":"Elderly inflammatory bowel disease patients: patient and disease characteristics","authors":"Filip Babić, P. Čačić, Dominik Kralj, A. Bišćanin, V. Tomašić, I. Burčul, Doris Ogresta Kordej, Z. Dorosulić, D. Hrabar","doi":"10.26800/lv-145-supl9-25","DOIUrl":null,"url":null,"abstract":"Results : A total of 184 non-elderly and 11 elderly patients were analyzed. Baseline IBD patient and disease characteristics were comparable in elderly and non-elderly group as there was no statistically significant difference in female or smoking rates, as well as in disease duration or extraintestinal manifestations rates. When comparing treatment data, anti-TNFα drugs were used significantly less in the elderly group (p=0.001). Combination therapy with an immunomodulator and a biologic (combotherapy) was evaluated on patients starting anti-TNFα drugs and was significantly higher in the non-elderly patient group (p=0.02","PeriodicalId":246678,"journal":{"name":"Liječnički vjesnik","volume":" 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liječnički vjesnik","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26800/lv-145-supl9-25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Results : A total of 184 non-elderly and 11 elderly patients were analyzed. Baseline IBD patient and disease characteristics were comparable in elderly and non-elderly group as there was no statistically significant difference in female or smoking rates, as well as in disease duration or extraintestinal manifestations rates. When comparing treatment data, anti-TNFα drugs were used significantly less in the elderly group (p=0.001). Combination therapy with an immunomodulator and a biologic (combotherapy) was evaluated on patients starting anti-TNFα drugs and was significantly higher in the non-elderly patient group (p=0.02